UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
|
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
(State or Other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
(
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each Class |
Trading Symbol |
Name of Each Exchange on Which Registered |
|
|
|
|
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer ☐ |
|
Non-accelerated filer ☐ |
Smaller reporting company |
Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
APPLICABLE ONLY TO CORPORATE ISSUERS:
As of April 30, 2025, there were
ANIKA THERAPEUTICS, INC.
TABLE OF CONTENTS
References in this Quarterly Report on Form 10-Q to “we,” “us,” “our,” “our company,” and other similar references refer to Anika Therapeutics, Inc. and its subsidiaries unless the context otherwise indicates.
ANIKA, ANIKA THERAPEUTICS, CINGAL, HYAFF, HYALOFAST, INTEGRITY, MONOVISC, ORTHOVISC, and TACTOSET are our registered trademarks that appear in this Quarterly Report on Form 10-Q. For convenience, these trademarks appear in this Quarterly Report on Form 10-Q without ® and ™ symbols, but that practice does not mean that we will not assert, to the fullest extent under applicable law, our rights to the trademarks. This Quarterly Report on Form 10-Q also contains trademarks and trade names that are the property of other companies and licensed to us.
|
PART I: |
|
|
ITEM 1. |
Anika Therapeutics, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands, except per share data)
(unaudited)
|
March 31, |
December 31, |
|||||||
|
ASSETS |
2025 |
2024 |
||||||
|
Current assets: |
||||||||
|
Cash and cash equivalents |
$ | $ | ||||||
|
Accounts receivable, net |
||||||||
|
Inventories, net |
||||||||
|
Prepaid expenses and other current assets |
||||||||
|
Current assets held for sale |
||||||||
|
Total current assets |
||||||||
|
Property and equipment, net |
||||||||
|
Right-of-use assets |
||||||||
|
Other long-term assets |
||||||||
|
Notes receivable |
||||||||
|
Deferred tax assets |
||||||||
|
Intangible assets, net |
||||||||
|
Goodwill |
||||||||
|
Non-current assets held for sale |
||||||||
|
Total assets |
$ | $ | ||||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||
|
Current liabilities: |
||||||||
|
Accounts payable |
$ | $ | ||||||
|
Accrued expenses and other current liabilities |
||||||||
|
Current liabilities held for sale |
||||||||
|
Total current liabilities |
||||||||
|
Other long-term liabilities |
||||||||
|
Lease liabilities |
||||||||
|
Non-current liabilities held for sale |
||||||||
|
Commitments and contingencies (Note 9) |
|
|
||||||
|
Stockholders’ equity: |
||||||||
|
Preferred stock, $ |
||||||||
|
Common stock, $ |
||||||||
|
Additional paid-in-capital |
||||||||
|
Accumulated other comprehensive loss |
( |
) |
( |
) |
||||
|
Retained earnings |
||||||||
|
Total stockholders’ equity |
||||||||
|
Total liabilities and stockholders’ equity |
$ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Anika Therapeutics, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share data)
(unaudited)
|
Three Months Ended March 31, |
||||||||
|
2025 |
2024 |
|||||||
|
Revenue |
$ | $ | ||||||
|
Cost of revenue |
||||||||
|
Gross Profit |
||||||||
|
Operating expenses: |
||||||||
|
Research and development |
||||||||
|
Selling, general and administrative |
||||||||
|
Total operating expenses |
||||||||
|
Loss from operations |
( |
) |
( |
) |
||||
|
Interest and other income (expense), net |
||||||||
|
Loss before income taxes |
( |
) |
( |
) |
||||
|
Provision for income taxes |
||||||||
|
Loss from continuing operations |
( |
) | ( |
) | ||||
|
Loss from discontinued operations, net of tax |
( |
) | ( |
) | ||||
|
Net loss |
$ | ( |
) | $ | ( |
) | ||
|
Loss per share: |
||||||||
|
Basic |
||||||||
|
Continuing operations |
( |
) | $ | ( |
) | |||
|
Discontinued operations |
( |
) | ( |
) | ||||
| $ | ( |
) | $ | ( |
) | |||
|
Diluted |
||||||||
|
Continuing operations |
( |
) | $ | ( |
) | |||
|
Discontinued operations |
( |
) | ( |
) | ||||
| $ | ( |
) | $ | ( |
) | |||
|
Weighted average common shares outstanding: |
||||||||
|
Basic |
||||||||
|
Diluted |
||||||||
|
Net loss |
$ | ( |
) | $ | ( |
) | ||
|
Foreign currency translation adjustment |
( |
) | ||||||
|
Comprehensive loss |
$ | ( |
) | $ | ( |
) | ||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Anika Therapeutics, Inc. and Subsidiaries
Condensed Consolidated Statements of Stockholders' Equity
(in thousands, except per share data)
(unaudited)
|
Three Months Ended March 31, 2025 |
||||||||||||||||||||||||
|
Common Stock |
Accumulated |
|||||||||||||||||||||||
|
Additional |
Other |
Total |
||||||||||||||||||||||
|
Number of |
$.01 Par |
Paid |
Retained |
Comprehensive |
Stockholders' |
|||||||||||||||||||
|
Shares |
Value |
in Capital |
Earnings |
Loss |
Equity |
|||||||||||||||||||
|
Balance, January 1, 2025 |
$ | $ | $ | $ | ( |
) |
$ | |||||||||||||||||
|
Vesting of restricted stock units |
||||||||||||||||||||||||
|
Stock-based compensation expense |
- | |||||||||||||||||||||||
|
Retirement of common stock for minimum tax withholdings |
( |
) |
( |
) |
( |
) |
( |
) |
||||||||||||||||
|
Repurchase of common stock |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||
|
Net loss |
- | ( |
) |
( |
) |
|||||||||||||||||||
|
Other comprehensive loss |
- | |||||||||||||||||||||||
|
Balance, March 31, 2025 |
$ | $ | $ | $ | ( |
) |
$ | |||||||||||||||||
|
Three Months Ended March 31, 2024 |
||||||||||||||||||||||||
|
Common Stock |
Accumulated |
|||||||||||||||||||||||
|
Additional |
Other |
Total |
||||||||||||||||||||||
|
Number of |
$.01 Par |
Paid |
Retained |
Comprehensive |
Stockholders' |
|||||||||||||||||||
|
Shares |
Value |
in Capital |
Earnings |
Loss |
Equity |
|||||||||||||||||||
|
Balance, January 1, 2024 |
$ | $ | $ | $ | ( |
) |
$ | |||||||||||||||||
|
Issuance of common stock for equity awards |
||||||||||||||||||||||||
|
Vesting of restricted stock units |
( |
) |
||||||||||||||||||||||
|
Stock-based compensation expense |
- | |||||||||||||||||||||||
|
Retirement of common stock for minimum tax withholdings |
( |
) |
( |
) | ( |
) | ( |
) | ||||||||||||||||
|
Net loss |
- | ( |
) |
( |
) |
|||||||||||||||||||
|
Other comprehensive income |
- | ( |
) | ( |
) | |||||||||||||||||||
|
Balance, March 31, 2024 |
$ | $ | $ | $ | ( |
) |
$ | |||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Anika Therapeutics, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
|
Three Months Ended March 31, |
||||||||
|
2025 |
2024 |
|||||||
|
(a) |
(a) |
|||||||
|
Cash flows from operating activities: |
||||||||
|
Net loss |
$ | ( |
) |
$ | ( |
) |
||
|
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
|
Depreciation |
||||||||
|
Amortization of acquisition related intangible assets |
||||||||
|
Non-cash operating lease cost |
||||||||
|
Stock-based compensation expense |
||||||||
|
Deferred income taxes |
||||||||
|
Provision for credit losses |
( |
) | ||||||
|
Provision for inventory |
||||||||
|
Interest income on notes receivable |
( |
) | ||||||
|
Gain on sale of Parcus Medical |
( |
) | ||||||
|
Changes in operating assets and liabilities: |
||||||||
|
Accounts receivable |
||||||||
|
Inventories |
( |
) | ||||||
|
Prepaid expenses, other current and long-term assets |
( |
) | ( |
) | ||||
|
Accounts payable |
||||||||
|
Operating lease liabilities |
( |
) |
( |
) | ||||
|
Accrued expenses, other current and long-term liabilities |
( |
) |
( |
) | ||||
|
Income taxes |
( |
) | ||||||
|
Net cash used in operating activities |
( |
) | ( |
) | ||||
|
Cash flows from investing activities: |
||||||||
|
Proceeds from sale of Parcus Medical, net of cash |
||||||||
|
Purchases of property and equipment |
( |
) |
( |
) |
||||
|
Net cash provided by (used in) investing activities |
( |
) | ||||||
|
Cash flows from financing activities: |
||||||||
|
Repurchases of common stock |
( |
) | ||||||
|
Cash paid for tax withheld on vested restricted stock awards |
( |
) |
( |
) |
||||
|
Proceeds from exercises of equity awards |
||||||||
|
Net cash used in financing activities |
( |
) |
( |
) |
||||
|
Exchange rate impact on cash |
( |
) | ||||||
|
Decrease in cash and cash equivalents |
( |
) |
( |
) |
||||
|
Cash and cash equivalents at beginning of period |
||||||||
|
Cash and cash equivalents at end of period |
$ | $ | ||||||
|
Supplemental disclosure of cash flow information: |
||||||||
|
Non-cash investing activities: |
||||||||
|
Purchases of property and equipment included in accounts payable and accrued expenses |
$ | $ | ||||||
|
(a) |
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Anika Therapeutics, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(amounts in thousands, except share and per share amounts or as otherwise noted)
(unaudited)
|
1. |
Nature of Business |
Anika Therapeutics, Inc. (the “Company”) is a global joint preservation company in osteoarthritis (“OA”) pain management and regenerative solutions, focusing on early intervention orthopedics. The Company offers hyaluronic acid-based advancements in its OA Pain Management and Regenerative Solutions businesses, all designed to restore active living, empower surgeon choice, and enhance patient outcomes worldwide.
In early 2020, the Company expanded its overall technology platform through its strategic acquisitions of Parcus Medical, LLC (“Parcus Medical”), a sports medicine implant and instrumentation company, and Arthrosurface Incorporated (“Arthrosurface”), a company specializing in less invasive, bone preserving partial and total joint replacement solutions. These acquisitions broadened the Company's product portfolio, developed over its 30 years of expertise in hyaluronic acid technology, into joint preservation and restoration, increased its commercial capabilities, diversified its revenue base, and expanded its product pipeline and research and development expertise.
In October 2024, the Company announced a strategic shift to focus on its OA Pain Management and Regenerative Solutions businesses. This strategic decision resulted in the sale of Arthrosurface on October 31, 2024 and the sale of Parcus Medical on March 7, 2025.
The Company is subject to risks common to companies in the life sciences industry including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration (“FDA”) and foreign regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.
|
2. |
Basis of Presentation |
The accompanying unaudited condensed consolidated financial statements and related notes have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The financial statements include the accounts of Anika Therapeutics, Inc. and its subsidiaries. Inter-company transactions and balances have been eliminated. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to SEC rules and regulations relating to interim financial statements. The December 31, 2024 balances reported herein were derived from the audited consolidated financial statements. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary to fairly state the condensed consolidated financial statements.
The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company’s annual financial statements filed with its Annual Report on Form 10-K for the year ended December 31, 2024. The results of operations for the three-month period ended March 31, 2025 are not indicative of the results to be expected for the year ending December 31, 2025.
As noted above, the Company made a strategic decision in October 2024 that resulted in the sales of Arthrosurface and Parcus Medical. See Note 3, Discontinued Operations, for further information. The condensed consolidated financial statements reflect Arthrosurface and Parcus Medical’s results of operations as discontinued operations for all periods presented, and the related assets and liabilities as held-for-sale as of December 31, 2024.
Recent Issued Accounting Pronouncements
In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (“ASU”) No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which establishes new income tax disclosure requirements in addition to modifying and eliminating certain existing requirements. Under the new guidance, entities must consistently categorize and provide greater disaggregation of information in the rate reconciliation and must also disaggregate income taxes paid. ASU 2023-09 is effective for fiscal years and interim periods beginning after December 15, 2024. The Company is evaluating the impact of ASU 2023-09 on its consolidated financial statements and related disclosures.
In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, and in January 2025, the FASB issued ASU No. 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. ASU 2024-03 requires additional disclosure of the nature of expenses included in the income statement as well as disclosures about specific types of expenses included in the expense captions presented in the income statement. ASU 2024-03, as clarified by ASU 2025-01, is effective for public companies for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is evaluating the impact of ASU 2024-03 on its disclosures in future years as a result of the adoption of ASU 2024-03.
|
3. |
Discontinued Operations |
In October 2024, the Company announced a strategic shift to focus on its OA Pain Management and Regenerative Solutions businesses. This strategic decision resulted in the sale of Arthrosurface on October 31, 2024 and the sale of Parcus Medical on March 7, 2025.
Arthrosurface
On October 31, 2024 (the “Closing Date”), the Company completed the sale of all of the outstanding equity interests of Arthrosurface, a Delaware corporation and former wholly-owned subsidiary of the Company, which held the Company’s Arthrosurface business, to Phoenix Brio, Incorporated, a Delaware corporation (the “Buyer”), pursuant to the terms and conditions of a Share Purchase Agreement, dated as of the Closing Date (the “Purchase Agreement”), by and among the Company, Arthrosurface and Buyer (the “Arthrosurface Transaction”).
As consideration for the Arthrosurface Transaction, at the closing, the Buyer delivered to the Company a ten-year non-interest-bearing promissory note in the principal amount of $
Parcus Medical
On March 7, 2025, the Company completed the sale of all outstanding equity interests of Parcus Medical, to Medacta Americas Manufacturing, Inc. (“Medacta”), pursuant to the terms and conditions of a Membership Interest Purchase Agreement (the “Parcus Transaction”). As consideration for the Parcus Transaction, at closing, Medacta paid $
The components of loss from discontinued operations for the three months ended March 31, 2025 and 2024, consist of the following (in thousands):
|
Three Months Ended March 31, |
||||||||
|
2025 |
2024 |
|||||||
|
Revenue |
$ | $ | ||||||
|
Costs and expenses |
||||||||
|
Loss from discontinued operations |
$ | ( |
) | $ | ( |
) | ||
For the three months ended March 31, 2025 and 2024, there was no income tax expense associated with discontinued operations.
The assets and liabilities reported as held-for-sale consist of the following (in thousands):
|
As of December 31, |
||||
|
2024 |
||||
|
Assets |
||||
|
Cash and cash equivalents |
$ | |||
|
Accounts receivable, net |
||||
|
Inventories |
||||
|
Prepaid expenses and other current assets |
||||
|
Property and equipment, net |
||||
|
Right-of-use assets |
||||
|
Total assets held-for-sale |
$ | |||
|
Liabilities |
||||
|
Accounts payable |
$ | |||
|
Accrued expenses and other current liabilities |
||||
|
Lease liabilities |
||||
|
Total liabilities held-for-sale |
$ | |||
There are no assets and liabilities reported as held-for-sale as of March 31, 2025, as the Company completed the divestitures of the Arthrosurface and Parcus Medical asset groups prior to March 31, 2025.
Selected financial information related to significant operating and investing cash flow items from discontinued operations (excluding working capital impacts) are as follows (in thousands):
|
Three Months Ended March 31, |
||||||||
|
2025 |
2024 |
|||||||
|
Depreciation |
$ | $ | ||||||
|
Amortization of acquisition related intangible assets |
$ | $ | ||||||
|
Non-cash operating lease cost |
$ | $ | ||||||
|
Stock-based compensation expense |
$ | $ | ||||||
|
Provision for inventory |
$ | $ | ||||||
|
Purchases of property and equipment |
$ | $ | ||||||
|
4. |
Accounts Receivable |
The Company estimates an allowance for credit losses with its accounts receivable resulting from the inability of its customers to make required payments, which is included in selling, general and administrative expenses in the accompanying consolidated statements of operations. In determining the adequacy of the allowance, management specifically analyzes individual accounts receivable, historical bad debts, customer concentrations, customer creditworthiness, current and reasonable and supportable forecasts of future economic conditions, accounts receivable aging trends, and changes in the Company’s customer payment terms.
The components of the Company’s accounts receivable are as follows:
|
As of |
As of |
|||||||
|
March 31, |
December 31, |
|||||||
|
2025 |
2024 |
|||||||
|
Accounts Receivable |
$ | $ | ||||||
|
Less: Allowance for credit losses |
||||||||
|
Net balance, end of period |
$ | $ | ||||||
A summary of activity in the allowance for credit losses is as follows:
|
As of March 31, |
||||||||
|
2025 |
2024 |
|||||||
|
Balance, beginning of the period |
$ | $ | ||||||
|
Amounts provided |
||||||||
|
Amounts recovered |
( |
) |
( |
) |
||||
|
Amounts written off |
( |
) | ||||||
|
Translation adjustments |
( |
) |
||||||
|
Balance, end of period |
$ | $ | ||||||
|
5. |
Fair Value Measurements |
The Company has certain cash equivalents in money market funds that are classified within Level 1 of the fair value hierarchy and are valued based on quoted prices in active markets. For cash, accounts receivable, notes receivable, accounts payable, and accrued interest, the carrying amounts approximate fair value, because of the short maturity of these instruments, and therefore fair value information is not included in the table below. There were no transfers between fair value levels during the three-month periods ended March 31, 2025 and December 31, 2024, respectively.
The classification of the Company’s cash equivalents within the fair value hierarchy was as follows:
|
March 31, |
Active |
Significant |
Significant |
Amortized |
||||||||||||||||
|
2025 |
(Level 1) |
(Level 2) |
(Level 3) |
Cost |
||||||||||||||||
|
Cash equivalents: |
||||||||||||||||||||
|
Money Market Funds |
$ | $ | $ | $ | $ | |||||||||||||||
|
December 31, |
Active |
Significant |
Significant |
Amortized |
||||||||||||||||
|
2024 |
(Level 1) |
(Level 2) |
(Level 3) |
Cost |
||||||||||||||||
|
Cash equivalents: |
||||||||||||||||||||
|
Money Market Funds |
$ | $ | $ | $ | $ | |||||||||||||||
|
6. |
Inventories |
Inventories consist of the following:
|
March 31, |
December 31, |
|||||||
|
2025 |
2024 |
|||||||
|
Raw materials |
$ | $ | ||||||
|
Work-in-process |
||||||||
|
Finished goods |
||||||||
|
Total |
$ | $ | ||||||
|
Inventories |
$ | $ | ||||||
|
Other long-term assets |
||||||||
|
Total |
$ | $ | ||||||
Inventories are stated net of inventory reserves of approximately $
|
7. |
Property and Equipment |
Property and equipment is stated at cost and consists of the following:
|
March 31, |
December 31, |
|||||||
|
2025 |
2024 |
|||||||
|
Equipment and software |
$ | $ | ||||||
|
Furniture and fixtures |
||||||||
|
Leasehold improvements |
||||||||
|
Construction in progress |
||||||||
|
Subtotal |
||||||||
|
Less accumulated depreciation |
( |
) | ( |
) | ||||
|
Total |
$ | $ | ||||||
Depreciation expense was $
|
8. |
Intangible Assets |
Intangible assets as of March 31, 2025 and December 31, 2024 consisted of the following:
|
December 31, |
||||||||||||||||||||||||
| Three Months Ended March 31, 2025 |
2024 |
|||||||||||||||||||||||
|
Less: |
||||||||||||||||||||||||
|
Accumulated |
Weighted |
|||||||||||||||||||||||
|
Currency |
Less: |
Average |
||||||||||||||||||||||
|
Gross |
Translation |
Accumulated |
Net Book |
Net Book |
Useful |
|||||||||||||||||||
|
Value |
Adjustment |
Amortization |
Value |
Value |
Life |
|||||||||||||||||||
|
Developed technology |
$ | $ | ( |
) |
$ | ( |
) |
$ | $ | |||||||||||||||
|
IPR&D |
( |
) | - |
Indefinite |
||||||||||||||||||||
|
Distributor relationships |
( |
) | ( |
) | ||||||||||||||||||||
|
Patents |
( |
) | ( |
) | ||||||||||||||||||||
|
Total |
$ | $ | ( |
) |
$ | ( |
) |
$ | $ | |||||||||||||||
The aggregate amortization expense related to intangible assets was $
As of March 31, 2025, the scheduled amortization of intangible assets is as follows:
|
Remainder of 2025 |
$ | |||
|
2026 |
||||
|
2027 |
||||
|
Total |
$ |
|
9. |
Goodwill |
The Company assesses goodwill for impairment annually, or, under certain circumstances, more frequently, such as when events or changes in circumstances indicate there may be impairment.
Changes in the carrying value of goodwill for the three-months ended March 31, 2025 were as follows:
|
Three Months Ended |
||||
|
2025 |
||||
|
Balance, beginning of period |
$ | |||
|
Effect of foreign currency adjustments |
||||
|
Balance, ending of period |
$ | |||
|
10. |
Accrued Expenses and Other Current Liabilities |
Accrued expenses and other current liabilities consist of the following:
|
March 31, |
December 31, |
|||||||
|
2025 |
2024 |
|||||||
|
Compensation and related expenses |
$ | $ | ||||||
|
Professional fees |
||||||||
|
Operating lease liability – current |
||||||||
|
Clinical trial costs |
||||||||
|
Share based compensation |
||||||||
|
Income taxes payable |
||||||||
|
Other |
||||||||
|
Total |
$ | $ | ||||||
|
11. |
Commitments and Contingencies |
In certain of its contracts, the Company warrants to customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the specific product. The Company may also warrant that the products it manufactures do not infringe, violate, or breach any U.S. or international patent or intellectual property right, trade secret, or other proprietary information of any third party. On occasion, the Company contractually indemnifies its customers against any and all losses arising out of, or in any way connected with, any claim or claims of breach of its warranties or any actual or alleged defect in any product caused by the negligent acts or omissions of the Company. The Company maintains a products liability insurance policy that limits its exposure to these risks. Based on the Company’s historical activity, in combination with its liability insurance coverage, the Company believes the estimated fair value of these indemnification agreements is immaterial. The Company had accrued warranties as of March 31, 2025 or December 31, 2024 and has no history of claims paid.
The Company is also involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, the Company does not expect the resolution of these occasional legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flow.
|
12. |
Revenue and Geographic Information |
Revenue by product classification is as follows:
|
Three Months Ended March 31, |
||||||||
|
2025 |
2024 |
|||||||
|
Original Equipment Manufacturer (“OEM”) Channel |
$ | $ | ||||||
|
Commercial Channel |
||||||||
|
Total |
$ | $ | ||||||
Revenue from the Company’s sole significant customer, Johnson & Johnson MedTech (“J&J MedTech”), part of the Johnson & Johnson Medical Companies, as a percentage of the Company’s total revenue was
Total revenue by geographic location based on the location of the customer in total and as a percentage of total revenue were as follows:
|
Three Months Ended March 31, |
||||||||||||||||
|
2025 |
2024 |
|||||||||||||||
|
Percentage of |
Percentage of |
|||||||||||||||
|
Revenue |
Revenue |
Revenue |
Revenue |
|||||||||||||
|
Geographic Location: |
||||||||||||||||
|
United States |
$ |
% |
$ |
% |
||||||||||||
|
Europe |
% |
% |
||||||||||||||
|
Other |
% |
% |
||||||||||||||
|
Total |
$ |
% |
$ |
% |
||||||||||||
|
13. |
Equity Incentive Plans |
Equity Incentive Plans
The Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (the “2017 Plan”) was approved by the Company’s stockholders on June 13, 2017 and subsequently amended on June 18, 2019, June 16, 2020, June 16, 2021, June 8, 2022 and June 14, 2023. On June 14, 2023, the Company’s stockholders approved an amendment to the 2017 Plan increasing the number of shares by
The Anika Therapeutics, Inc. 2021 Inducement Plan (the “Inducement Plan”) was adopted by the Company’s board of directors on November 4, 2021 and subsequently amended on December 22, 2023 and May 2, 2024. On May 2, 2024, the Company’s board of directors approved an amendment to the Inducement Plan increasing the number of shares by
The Company may satisfy share-settled awards upon exercise, or upon fulfillment of the vesting requirements for other equity-based awards, with either newly issued shares or shares reacquired by the Company. Stock-based awards are granted with an exercise price equal to or greater than the market price of the Company’s stock on the date of grant. Awards contain service conditions or service and performance conditions, and they generally become exercisable ratably over years with a maximum contractual term of years.
The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to each of its employees as follows (in thousands):
|
Three Months Ended March 31, |
||||||||
|
2025 |
2024 |
|||||||
|
Cost of revenue |
$ | $ | ||||||
|
Research and development |
||||||||
|
Selling, general and administrative |
||||||||
|
Total stock-based compensation expense |
$ | $ | ||||||
Stock Options
Stock options are granted to purchase common shares at prices that are equal to the fair market value of the shares on the date the options are granted or, in the case of premium options, are granted with an exercise price at
The following summarizes the activity under the Company’s stock option plans:
|
Weighted |
||||||||||||||||
|
Average |
||||||||||||||||
|
Weighted |
Remaining |
Aggregate |
||||||||||||||
|
Average |
Contractual |
Intrinsic |
||||||||||||||
|
Number of |
Exercise |
Term |
Value |
|||||||||||||
|
Options |
Price |
(in years) |
(in thousands) |
|||||||||||||
|
Outstanding as of December 31, 2024 |
$ | $ | ||||||||||||||
|
Granted |
$ | |||||||||||||||
|
Exercised |
$ |
$ | ||||||||||||||
|
Forfeited and canceled |
( |
) |
$ | $ | ||||||||||||
|
Outstanding as of March 31, 2025 |
$ | $ | ||||||||||||||
|
Vested, March 31, 2025 |
$ | $ | - | |||||||||||||
|
Vested or expected to vest, March 31, 2025 |
$ | $ | - | |||||||||||||
The aggregate intrinsic value of options exercised for the three-month period ended March 31, 2025 was immaterial. The Company did grant any stock options during the three-months ended March 31, 2025.
The Company uses the Black-Scholes pricing model to determine the fair value of options granted. The calculation of the fair value of stock options is affected by the stock price on the grant date, the expected volatility of the Company’s common stock over the expected term of the award, the expected life of the award, the risk-free interest rate and the dividend yield.
Listed below are the assumptions used in the Black-Scholes pricing model for options granted during the three months ended March 31, 2024. There were no options granted during the three months ended March 31, 2025. The assumptions were as follows:
|
Three Months Ended |
||||||||||||
|
March 31, |
||||||||||||
|
2024 |
||||||||||||
|
Risk free interest rate |
% | - | % | |||||||||
|
Expected volatility |
% | - | % | |||||||||
|
Expected life (years) |
||||||||||||
|
Expected dividend yield |
% | |||||||||||
|
Fair value per option |
$ | |||||||||||
As of March 31, 2025, there was $
Restricted Stock Units (“RSUs”)
RSUs generally vest in equal annual installments over a -year period. The grant-date fair value of RSUs is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company determines the fair value of RSUs based on the closing price of its common stock on the date of grant.
RSU activity for the three-month period ended March 31, 2025 was as follows:
|
Weighted |
||||||||
|
Number of |
Average |
|||||||
|
Shares |
Fair Value |
|||||||
|
Outstanding as of December 31, 2024 |
$ | |||||||
|
Granted |
$ | |||||||
|
Vested |
( |
) |
$ | |||||
|
Forfeited and cancelled |
( |
) |
$ | |||||
|
Outstanding as of March 31, 2025 |
$ | |||||||
The weighted-average grant-date fair value per share of RSUs granted was $
The Company’s annual grants of RSU awards in March 2024 and 2025 can be settled at vesting in cash or shares at the Company’s election. The Company has recorded these RSUs as a liability due to the expectation that the Company will settle the vesting of these RSU awards in cash due to a potential shortage of shares in the 2017 Plan at the time of vesting. As a result, these RSUs will be subject to change in value at the time of each reporting period. The first tranche of the March 2024 RSU awards,
Performance Stock Units (“PSUs”)
PSU activity for the three-month period ended March 31, 2025 was as follows:
|
Weighted |
||||||||
|
Number of |
Average |
|||||||
|
Shares |
Fair Value |
|||||||
|
Outstanding as of December 31, 2024 |
$ | |||||||
|
Granted |
$ | |||||||
|
Vested |
$ | |||||||
|
Forfeited and cancelled |
$ | |||||||
|
Outstanding as of March 31, 2025 |
$ | |||||||
The weighted-average grant-date fair value per share of PSUs granted was $
The Company’s annual grants of PSU awards in March 2025 can be settled at vesting in cash or shares at the Company’s election. The Company has recorded these PSUs as a liability due to the expectation that the Company will settle the vesting of these PSU awards in cash due to a potential shortage of shares in the 2017 Plan at the time of vesting. As a result, these PSUs will be subject to change in value at the time of each reporting period. As of March 31, 2025, the Company had
On March 14, 2025, the Company granted
|
14. |
Income Taxes |
The income tax expense was $
The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, carryback potential if permitted under the tax law, and results of recent operations. The Company has incurred operating losses in recent years. As a result, the Company anticipates that deferred tax assets originating during the year ended December 31, 2025 will exceed the availability of reversing taxable temporary differences. Due to significant negative evidence, including the Company’s prior year operating losses, the Company concluded its anticipated net deferred tax assets in the U.S. are not more likely than not to be realizable. Accordingly, the income tax provision for the three-month period ended March 31, 2025 includes an adjustment for the valuation allowance required against the U.S deferred tax assets. As of March 31, 2025, the Company continues to believe its foreign deferred tax assets are realizable based upon future reversals of existing taxable temporary differences and projected future taxable income.
The Company files income tax returns in the United States on a federal basis, in certain U.S. states, and in certain foreign jurisdictions. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate, which varies by jurisdiction. In September 2024, the Company was notified by the Italian tax authorities that it had selected the Company’s tax returns for its Italian subsidiary for
|
15. |
Earnings Per Share (“EPS”) |
Basic EPS is calculated by dividing net income (loss) by the weighted average number of shares outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are not considered outstanding for purposes of calculating basic EPS. Diluted EPS is calculated by dividing net income by the weighted average number of shares outstanding plus the dilutive effect, if any, of outstanding share-based awards using the treasury stock method. Due to the Company’s loss position, the share-based payment awards are anti-dilutive.
The Company had a net loss during the three-month periods ended March 31, 2025 and 2024, respectively, and therefore all potential common shares would have been anti-dilutive and accordingly were excluded from the computation of diluted EPS. Stock options of
|
16. |
Share Repurchase |
In May 2024, the Company agreed to implement a share repurchase program for an aggregate purchase price of $
On May 28, 2024, the Company entered into a share repurchase agreement under a Rule 10b5-1 Plan with Bank of America. As of March 31, 2025, the Company completed the first part of the share repurchase program in which it purchased
|
17. |
Segment Information |
Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker (“CODM”) in deciding how to allocate resources and assess performance. The Company operates in business segment. The Company’s CODM is its President and Chief Executive Officer, who reviews financial information presented on a consolidated basis. The CODM’s financial review is focused on the consolidated financial results of the Company which is used as the basis for financial performance assessment and allocation of resources.
The following table presents financial information with respect to the Company’s single operating segment for the three months ended March 31, 2025 and 2024 (in thousands):
|
Three Months Ended March 31, |
||||||||
|
2025 |
2024 |
|||||||
|
Revenue |
$ | $ | ||||||
|
Cost of revenue |
||||||||
|
Gross Profit |
||||||||
|
Operating expenses: |
||||||||
|
Research and development |
||||||||
|
Selling, general and administrative |
||||||||
|
Total operating expenses |
||||||||
|
Loss from operations |
( |
) | ( |
) | ||||
|
Interest and other income (expense), net |
||||||||
|
Loss before income taxes |
( |
) | ( |
) | ||||
|
Provision for income taxes |
||||||||
|
Loss from continuing operations |
( |
) | ( |
) | ||||
|
Loss from discontinued operations, net of tax |
( |
) | ( |
) | ||||
|
Net loss |
$ | ( |
) | $ | ( |
) | ||
Total U.S revenues were $
|
ITEM 2. |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
You should read the following discussion in conjunction with our financial statements and related notes appearing elsewhere in this report and our audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the year ended December 31, 2024, or our 2024 Form 10-K. In addition to historical information, this report contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 concerning our business, consolidated financial condition, and results of operations. The Securities and Exchange Commission, or the SEC, encourages companies to disclose forward-looking statements so that investors can better understand a company’s future prospects and make informed investment decisions. Forward-looking statements are subject to risks and uncertainties, many of which are outside our control, which could cause actual results to differ materially from these statements. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements can be identified by such words as "will," "likely," "may," "believe," "expect," "anticipate," "intend," "seek," "designed," "develop," "would," "future," "can," "could," and other expressions that are predictions of or indicate future events and trends and that do not relate to historical matters. All statements other than statements of historical facts included in this report regarding our strategies, prospects, financial condition, operations, costs, plans, and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements regarding expected future operating results, expectations regarding the timing and receipt of regulatory results, anticipated levels of capital expenditures, and expectations of the effect on our financial condition of claims, litigation, and governmental and regulatory proceedings.
Please also refer to “Item 1A. Risk Factors” of our 2024 Form 10-K for important factors that we believe could cause actual results to differ materially from those in our forward-looking statements. Any forward-looking statement made by us in this report is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Management Overview
We are a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Based on our collaborations with clinicians to understand what they need most to treat their patients, we develop minimally invasive products that restore active living for people around the world. We are committed to leading in high opportunity spaces within orthopedics, including osteoarthritis, or OA, pain management and regenerative solutions.
We have over thirty years of global expertise developing, manufacturing and commercializing products based on our hyaluronic acid, or HA, technology platform. HA is a naturally occurring polymer found throughout the body that is vital for proper joint health and tissue function. Our proprietary technologies for modifying the HA molecule allow product properties to be tailored specifically to multiple uses, including enabling longer residence time to support OA pain management and creating a solid form of HA called Hyaff, which is a platform utilized in our Regenerative Solutions portfolio.
In early 2020, we expanded our overall technology platform, product portfolio, and significantly expanded our commercial infrastructure, especially in the United States, through our strategic acquisitions of Parcus Medical, LLC, or Parcus Medical, a sports medicine and instrumentation solutions provider, and Arthrosurface Incorporated, or Arthrosurface, a company specializing in bone preserving partial and total joint replacement solutions. These acquisitions augmented our HA-based OA Pain Management and Regenerative Solutions products with a broad suite of products and capabilities focused on early intervention joint preservation, primarily in upper and lower extremities such as shoulder, foot/ankle, knee and hand/wrist.
In October 2024, we announced a strategic shift to focus on our OA Pain Management and our Regenerative Solutions businesses. This strategic decision involved the sale of Arthrosurface in October 2024 and the sale of Parcus Medical in March 2025.
As we look towards the future, our business is positioned to capture value within our target markets of OA Pain Management and Regenerative Solutions. We believe our future success will be driven by our:
|
● |
Over 30 years of experience in HA and HA-based regenerative solutions and early intervention orthopedics, combined with seasoned leadership with a strong financial foundation for future investment in meaningful solutions for our customers and their patients; |
|
● |
Utilizing proprietary HA-based technology and manufacturing expertise to provide new and differentiated solutions in next generation OA pain management (e.g. Cingal) and regenerative (e.g. Integrity Implant System and Hyalofast) markets; |
|
● |
Growth of the Integrity Implant System, our hyaluronic acid-based scaffold for rotator cuff and other tendon repairs, launched in 2024; |
|
● |
Targeting to introduce key HA-based products into the US market upon FDA approval/clearance, such as Cingal and Hyalofast, and developing additional products that leverage our proprietary Hyaff regenerative platform; |
|
● |
Robust network of stakeholders in our target markets to identify evolving unmet patient treatment needs; |
|
● |
Global commercial expertise, which we will leverage to drive growth across our product portfolio, including continued international expansion; |
|
● |
Opportunity to pursue strategic inorganic growth opportunities, including potential partnerships and smaller acquisitions, technology licensing, and leveraging our strong financial foundation and operational capabilities; and |
|
● |
Energized and experienced team focused on strong values, talent, and culture. |
Products
OA Pain Management
Our OA Pain Management product family consists of Monovisc and Orthovisc, our injectable, HA-based OA pain management offerings that are indicated to provide pain relief from osteoarthritis conditions; and Cingal, our novel, single-injection OA Pain Management product consisting of our proprietary cross-linked HA material combined with a fast-acting steroid. Cingal is our next generation fast-acting, long-lasting, non-opioid, clinically proven osteoarthritis pain product which is designed to provide both short- and long-term pain relief through at least six months. It is currently sold outside the United States in over 35 countries. In 2022, we completed a third Phase III clinical trial for Cingal, which achieved its primary endpoint. Cingal is not currently approved for commercial use in the United States. We have been actively engaging with the U.S. Food and Drug Administration, or the FDA, on next steps for U.S. regulatory approval.
Regenerative Solutions
Our Regenerative Solutions product family consists of: (a) our portfolio of orthopedic regenerative solutions products utilizing HA, including Integrity, our hyaluronic acid-based scaffold for rotator cuff repair and other tendon procedures, Tactoset, an HA-enhanced, flowable, injectable and settable bone void filler used to facilitate bone regeneration and augment hardware in poor quality bone, and Hyalofast, a hyaluronic acid scaffold for cartilage repair, sold outside of the United States in over 30 countries.
Results of Operations
Three Months Ended March 31, 2025 Compared to Three Months Ended March 31, 2024
|
Three Months Ended March 31, |
||||||||||||||||
|
2025 |
2024 |
$ Change |
% Change |
|||||||||||||
|
(in thousands, except percentages) |
||||||||||||||||
|
Revenue |
$ | 26,168 | $ | 29,022 | $ | (2,854 | ) | (10 | %) | |||||||
|
Cost of revenue |
11,487 | 10,047 | 1,440 | 14 | % | |||||||||||
|
Gross profit |
14,681 | 18,975 | (4,294 | ) | (23 | %) | ||||||||||
|
Gross margin |
56 | % | 65 | % | ||||||||||||
|
Operating expenses: |
||||||||||||||||
|
Research and development |
6,059 | 6,409 | (350 | ) | (5 | %) | ||||||||||
|
Selling, general and administrative |
12,906 | 15,071 | (2,165 | ) | (14 | %) | ||||||||||
|
Total operating expenses |
18,965 | 21,480 | (2,515 | ) | (12 | %) | ||||||||||
|
Loss from operations |
(4,284 | ) | (2,505 | ) | (1,779 | ) | 71 | % | ||||||||
|
Interest and other income (expense), net |
415 | 592 | (177 | ) | (30 | %) | ||||||||||
|
Loss before income taxes |
(3,869 | ) | (1,913 | ) | (1,956 | ) | 102 | % | ||||||||
|
Provision for income taxes |
89 | 43 | 46 | 107 | % | |||||||||||
|
Loss from continuing operations |
(3,958 | ) | (1,956 | ) | (2,002 | ) | 102 | % | ||||||||
|
Loss from discontinued operations, net of tax |
(915 | ) | (2,558 | ) | 1,643 | (64 | %) | |||||||||
|
Net loss |
$ | (4,873 | ) | $ | (4,154 | ) | $ | (359 | ) | 8 | % | |||||
Revenue
The following table presents revenue by product family for the three-month period ended March 31, 2025 and 2024 as follows:
|
Three Months Ended March 31, |
||||||||||||||||
|
2025 |
2024 |
$ Change |
% Change |
|||||||||||||
|
(in thousands, except percentages) |
||||||||||||||||
|
Original Equipment Manufacturer (“OEM”) Channel |
$ | 14,909 | $ | 19,450 | $ | (4,541 | ) | (23 | %) | |||||||
|
Commercial Channel |
11,259 | 9,572 | 1,687 | 18 | % | |||||||||||
| $ | 26,168 | $ | 29,022 | $ | (2,854 | ) | (10 | %) | ||||||||
Revenue for the three-month period ended March 31, 2025 was $26.2 million, a decrease of $2.9 million, or 10%, compared to the same period in 2024. The decrease in revenue was driven by lower sales activity with our OEM Channel partners, primarily J&J MedTech and the discontinuation of certain non-orthopedic products.
Revenue from our OEM Channel product family decreased by 23% for the three-month period ended March 31, 2025, as compared to the same period in 2024, due primarily to lower pricing on sales to J&J MedTech, and lower revenue from J&J MedTech due to lower end user sales in 2025.
Revenue from our Commercial Channel product family increased 18% for the three-month period ended March 31, 2025, as compared to the same period in 2024, primarily due to higher international sales on our OA Pain Management products and growing commercial adoption of our newest products, particularly Integrity, which offset lower sales of certain legacy products.
Gross Profit and Margin
Gross profit for the three-month period ended March 31, 2025 decreased $4.3 million to $14.7 million, representing a 56% gross margin for the period as compared to 65% in the prior year. The decrease in gross profit for the three-month period ended March 31, 2025, as compared to the same period in 2024, primarily resulted from lower revenue and higher manufacturing costs. Gross margin for the three-month period ended March 31, 2025 decreased compared to the same period of prior year due to larger percentage of international sales that generally have a lower average selling price, higher manufacturing costs and increase in inventory reserves and scrap.
Research and Development
Research and development expenses for the three-month period ended March 31, 2025 were $6.1 million, a decrease of $0.3 million as compared to the same period in 2024. The decrease was primarily related to reduced headcount and lower product development and regulatory costs.
Selling, General and Administrative
Selling, general and administrative expenses for the three-month period ended March 31, 2025 were $12.9 million, a decrease of $2.2 million, as compared to the same period in 2024. This decrease for the three-month period ended March 31, 2025 was primarily due to reduced headcount, lower marketing expenses and other non-recurring corporate costs that occurred in 2024.
Loss from Continuing Operations
For the three-month period ended March 31, 2025, the loss from continuing operations was $4.0 million, compared to a loss from continuing operations of $2.0 million for the same period in 2024. The $2.0 million increase in the loss from continuing operations was due to lower revenue and higher manufacturing costs.
Income Taxes
The income tax expense was $0.1 million for the three-month period ended March 31, 2025, resulting in an effective tax rate of (2.3%). The income tax expense was immaterial for the three-month period ended March 31, 2024, resulting in an effective tax rate of (2.2%). The tax rates are consistent for the three-month period ended March 31, 2025, as compared to the same period in 2024, primarily due to a full valuation allowance being recorded against domestic deferred tax assets at March 31, 2024.
Non-GAAP Financial Measures
We present certain information with respect to adjusted Earnings Before Interest, Tax, Depreciation and Amortization, or EBITDA, adjusted net income, adjusted diluted earnings per share or adjusted EPS, which are financial measures not based on any standardized methodology prescribed by accounting principles generally accepted in the United States, or GAAP, and is not necessarily comparable to similarly titled measures presented by other companies.
We have presented adjusted EBITDA, adjusted net income, adjusted EPS, because they are key measures used by our management and board of directors to understand and evaluate our operating performance and to develop operational goals for managing our business. We believe these financial measures help identify underlying trends in our business that could otherwise be masked by the effect of the expenses that we exclude. In particular, we believe that the exclusion of these items in calculating these measures can provide a useful tool for period-to-period comparisons of our core operating performance. Accordingly, we believe that these measures provide useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects and allowing for greater transparency with respect to key financial metrics used by our management in their financial and operational decision-making.
Adjusted EBITDA
We present information below with respect to adjusted EBITDA, which we define as our net income (loss) excluding interest and other expense, net, income tax benefit, depreciation and amortization, stock-based compensation, and acquisition-related expenses.
Adjusted EBITDA is not prepared in accordance with GAAP, and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of adjusted EBITDA rather than net (loss) income, which is the nearest GAAP equivalent. Some of these limitations are:
|
● |
adjusted EBITDA excludes depreciation and amortization, and, although these are non-cash expenses, the assets being depreciated or amortized may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA; |
|
● |
we exclude share-based compensation expense from adjusted EBITDA although (a) it has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy and (b) if we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense included in operating expenses would be higher, which would affect our cash position; |
|
● |
the expenses and other items that we exclude in our calculation of adjusted EBITDA may differ from the expenses and other items, if any, that other companies may exclude from adjusted EBITDA when they report their operating results; |
The following is a reconciliation of adjusted EBITDA, a non-GAAP metric, to net loss, the most directly comparable GAAP financial measure, for the three-month periods ended March 31, 2025 and 2024, respectively:
|
Three Months Ended March 31, |
||||||||
|
2025 |
2024 |
|||||||
|
(in thousands) |
||||||||
|
Net loss from continuing operations |
$ | (3,958 | ) | $ | (1,956 | ) | ||
|
Interest and other (income) expense, net |
(415 | ) | (592 | ) | ||||
|
Provision for (benefit from) income taxes |
89 | 43 | ||||||
|
Depreciation and amortization |
1,416 | 1,374 | ||||||
|
Share-based compensation |
2,995 | 3,254 | ||||||
|
Costs of shareholder activism |
- | 601 | ||||||
|
Adjusted EBITDA |
$ | 127 | $ | 2,724 | ||||
Adjusted EBITDA in the three-month period ended March 31, 2025 decreased $2.6 million as compared with the same period in 2024. The decrease in adjusted EBITDA for the period was primarily due to a decrease in OEM Channel revenues and lower gross profit. .
Adjusted Net Income (Loss) and Adjusted EPS
We present information below with respect to adjusted net (loss) income and adjusted EPS. We define adjusted net (loss) income as our net (loss) income excluding amortization and depreciation of acquired assets, share-based compensation, and other non-recurring items, such as product rationalization charges, severance costs and costs of shareholder activism.. We define adjusted EPS as GAAP diluted earnings per share excluding the above adjustments to net (loss) income used in calculating adjusted net (loss) income, each on a per share and tax effected basis.
The following is a reconciliation of adjusted net loss, a non-GAAP metric, to net income (loss), the most directly comparable GAAP financial measure, for the three-month periods ended March 31, 2025 and 2024, respectively:
|
Three Months Ended March 31, |
||||||||
|
2025 |
2024 |
|||||||
|
(in thousands) |
||||||||
|
Net loss from continuing operations |
$ | (3,958 | ) | $ | (1,956 | ) | ||
|
Share-based compensation, tax effected |
3,063 | 3,285 | ||||||
|
Costs of shareholder activism, tax effected |
- | 607 | ||||||
|
Adjusted net income (loss) |
$ | (895 | ) | $ | 1,936 | |||
The following is a reconciliation of adjusted diluted EPS, a non-GAAP metric, to diluted EPS, the most directly comparable GAAP financial measure, for the three-month periods ended March 31, 2025 and 2024, respectively:
|
Three Months Ended March 31, |
||||||||
|
2025 |
2024 |
|||||||
|
Diluted loss per share |
$ | (0.28 | ) | $ | (0.13 | ) | ||
|
Share-based compensation, tax effected |
0.22 | 0.22 | ||||||
|
Costs of shareholder activism, tax effected |
- | 0.04 | ||||||
|
Adjusted diluted earnings (loss) per share |
$ | (0.06 | ) | $ | 0.13 | |||
Adjusted net income and adjusted diluted earnings per share in the three-month period ended March 31, 2025 decreased by $1.0 million and $0.19, respectively, as compared with the same period in 2024. The decrease for the period was primarily due to lower revenues and gross profit.
Liquidity and Capital Resources
We require cash to fund our operating activities and to make capital expenditures and other investments in the business. We expect that our requirements for cash to fund these uses will increase as our operations expand. We continue to generate cash from operating activities and believe that our operating cash flows, cash currently on our condensed consolidated balance sheet and availability under our credit facility will be sufficient to allow us to continue to invest in our existing business, to manage our capital structure on a short and long-term basis, and to meet our anticipated operating cash needs. Cash and cash equivalents aggregated $53.4 million and $55.6 million, and working capital totaled $84.6 million and $90.3 million, at March 31, 2025 and December 31, 2024, respectively.
On November 12, 2021, we entered into a Third Amendment to Credit Agreement with Bank of America N.A. as administrative agent, which amended our existing revolving line of credit agreement dated October 24, 2017 which provides up to $75.0 million in the form of a senior revolving line of credit. Subject to certain conditions, we may request up to an additional $75.0 million for a maximum aggregate commitment of $150.0 million. As of March 31, 2025, and December 31, 2024, there were no outstanding borrowings, and we are in compliance with the terms of the credit facility.
Summary of Cash Flows (in thousands):
|
Three Months Ended March 31, |
||||||||
|
2025 |
2024 |
|||||||
|
Cash provided by (used in) |
||||||||
|
Operating activities |
$ | (130 | ) | $ | (126 | ) | ||
|
Investing activities |
1,672 | (1,808 | ) | |||||
|
Financing activities |
(5,438 | ) | (2,273 | ) | ||||
|
Effect of exchange rate changes on cash |
108 | (31 | ) | |||||
|
Net decrease in cash and cash equivalents |
$ | (3,788 | ) | $ | (4,238 | ) | ||
The following changes contributed to the net change in cash and cash equivalents in the three-month period ended March 31, 2025 as compared to the same period in 2024.
Operating Activities
Cash used in operating activities was $0.1 million for each of the three-month periods ended March 31, 2025 and 2024, respectively. We had a slightly higher net loss during the three-month period ended March 31, 2025 that caused an increase in cash used in operating activities in 2024 offset by lower stock-based compensation, depreciation and amortization and improved working capital.
Investing Activities
Cash provided by investing activities was $1.7 million for the three-month period ended March 31, 2025, as compared to cash used in investing activities of $1.8 million for the same period in 2024. The change was primarily due to proceeds of $4.5 million from the sale of Parcus Medical offset by a $1.0 million increase in capital expenditures to support manufacturing operations at our Bedford facility.
Financing Activities
Cash used in financing activities was $5.4 million for the three-month period ended March 31, 2025, as compared to cash used in financing activities of $2.3 million for the same period in 2024. The increase in cash used in financing activities was primarily attributable to $4.0 million used to fund the share repurchase program that began in May 2024 and the utilization of cash for employee tax withholding in exchange for shares surrendered by equity award holders.
Critical Accounting Policies and Estimates
The preparation of our condensed consolidated financial statements in conformity with GAAP requires management to use judgment in making estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. We believe that our accounting policies for revenue recognition, accounts receivable and allowance for credit losses, goodwill, acquired in-process research and development, inventory and contingencies are based on, among other things, judgments and assumptions made by management that include inherent risks and uncertainties. There have been no significant changes to the above critical accounting policies or in the underlying accounting assumptions and estimates used in such policies from those disclosed in our annual consolidated financial statements and accompanying notes included in our 2024 Form 10-K for the year ended December 31, 2024. We monitor our estimates on an ongoing basis for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are recorded in the period in which they become known. We base our estimates on historical experience and other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be substantially accurate.
Recent Accounting Pronouncements
A discussion of Recent Accounting Pronouncements is included in our 2024 Form 10-K for the fiscal year ended December 31, 2024 and is updated in the Notes to the condensed consolidated financial statements included in this report.
Contractual Obligations and Other Commercial Commitments
Our contractual obligations and other commercial commitments are summarized in the section captioned “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—Contractual Obligations and Other Commercial Commitments” in our 2024 Form 10-K for the year ended December 31, 2024. There were no material changes to our contractual obligations reported in our 2024 Form 10-K during the three months ended March 31, 2025. For additional discussion, see Note 9 to the condensed consolidated financial statements included in this report.
To the extent that funds generated from our operations, together with our existing capital resources, are insufficient to meet future requirements, we will be required to obtain additional funds through equity or debt financings, strategic alliances with corporate partners and others, or through other sources. No assurance can be given that any additional financing will be made available to us or will be available on acceptable terms should such a need arise.
|
ITEM 3. |
Our market risks and the ways we manage them are summarized in the section captioned “Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report on Form 10-K for the year ended December 31, 2024. There have been no material changes in the first three months of 2025 to our market risks or to our management of such risks.
|
ITEM 4. |
(a) Evaluation of disclosure controls and procedures.
Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as defined by Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this report. Based upon that evaluation, the chief executive officer and chief financial officer have concluded as of March 31, 2025 that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in SEC rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by our company in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure. On an on-going basis, we review and document our disclosure controls and procedures, and our internal control over financial reporting, and may from time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business.
(b) Changes in internal controls over financial reporting.
There were no material changes in our internal control over financial reporting during the quarter ended March 31, 2025, that have materially affected, or were reasonably likely to materially affect, our internal control over financial reporting.
|
PART II: |
|
ITEM 1. |
We are involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, we do not expect the resolution of these occasional legal proceedings to have a material adverse effect on our financial position, results of operations, or cash flow. There have been no material changes to the information provided in the section captioned “Part I, Item 3. Legal Proceedings” in our Annual Report on Form 10-K for the year ended December 31, 2024.
|
ITEM 1A. |
Except as set forth below, there have been no material changes to the risk factors described in the section captioned “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024. In addition to the other information set forth in this report, you should carefully consider the factors discussed in the section captioned “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, which could materially affect our business, financial condition, or future results. The risks described in our Annual Report on Form 10-K and such subsequently filed Quarterly Report on Form 10-Q are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may have a material adverse effect on our business, financial condition, and/or operating results.
Significant political, trade, regulatory developments, and other circumstances beyond our control, could have a material adverse effect on our financial condition or results of operations.
Significant political, trade, or regulatory developments, such as those stemming from changes in the U.S. federal administration, are difficult to predict and may have a material adverse effect on us, as we both import materials and equipment necessary to manufacture our products in the U.S., and export materials and products from the U.S. Similarly, changes in U.S. federal policy that affect the geopolitical landscape could give rise to circumstances outside our control that could have negative impacts on our business operations. Changes to U.S. policy implemented by the U.S. Congress, the current administration or any new administration have impacted and may in the future impact, among other things, the U.S. and global economy, international trade relations, unemployment, immigration, healthcare, taxation, the U.S. regulatory environment, inflation and other areas. The United States has recently imposed blanket 10% tariffs on virtually all imports to the U.S. and has imposed or is considering imposing significantly higher so-called reciprocal tariffs applicable to imports from many countries. On April 9, 2025, the U.S. announced a temporary pause on its reciprocal tariffs applicable to many countries, while increasing the tariffs applicable to imports from China. The current administration has threatened to continue to broadly impose tariffs, which could lead to corresponding punitive actions by the countries with which the U.S. trades. Historically, tariffs have led to increased trade and political tensions. In response to tariffs, other countries have implemented retaliatory tariffs on U.S. goods. Political tensions as a result of trade policies could reduce trade volume, investment, technological exchange, and other economic activities between major international economies, resulting in a material adverse effect on global economic conditions and the stability of global financial markets. Any changes in political, trade, regulatory, and economic conditions, including U.S. trade policies, could have a material adverse effect on our financial condition or results of operations. Until we know what policy changes are made, whether those policy changes are challenged and subsequently upheld by the court system, the duration that those policy changes remain in effect, and how those changes impact our business and the business of our competitors over the long term, we will not know if, overall, we will benefit from them or be negatively affected by them.
|
ITEM 2. |
Issuer Purchases of Equity Securities
The following is a summary of stock repurchases for the three-month period ended March 31, 2025 (in thousands, except share and per share data):
|
Period |
(a) Total number of shares |
(b) Average |
(c) Total number of |
(d) Maximum number (or |
||||||||||||
|
January 1 to 31, 2025 |
122,414 | $ | 16.33 | 146,414 | $ | 27,094 | ||||||||||
|
February 1 to 28, 2025 |
106,235 | $ | 17.72 | 106,235 | $ | 25,212 | ||||||||||
|
March 1 to 31, 2025 |
11,879 | $ | 17.31 | 11,879 | $ | 25,000 | ||||||||||
|
Total |
240,528 | 240,528 | ||||||||||||||
(1) In May 2024, we agreed to implement a share repurchase program for an aggregate purchase price of $40.0 million to occur as follows: (i) first $15.0 million was to be effected through a Rule 10b5-1 plan initiated prior to June 1, 2024 and to be effective through June 30, 2025, and (ii) the remaining amount to be purchased in the open market (the “2024 Share Repurchase Program”). In the event of positive “free cash flow” as defined in the Cooperation Agreement dated May 28, 2024, with Caligan Partners LP, Caligan Partners Master Fund LP and David Johnson, for the period from July 1, 2024 through June 30, 2025, the amount under the share repurchase program shall be increased by 50% of such positive amount. In no event would we be required to make any purchases in the event that our cash would be less than $45.0 million after taking into account the share repurchase and reasonably anticipated capital expenditures and restructuring costs. This new authorization replaces our share repurchase program previously announced in April 2023. On May 28, 2024, the Company entered into a share repurchase agreement under a Rule 10b5-1 with Bank of America. As of March 31, 2025, the Company had repurchased 746,431 shares at an average cost of $20.10 per share, representing 38% of the then estimated total number of shares expected to be repurchased under the 2024 Share Repurchase Program.
Recent Sales of Unregistered Securities
None.
|
ITEM 3. |
None.
|
ITEM 4. |
Not applicable.
|
ITEM 5. |
Rule 10b5-1 Trading Plans
During the fiscal quarter ended March 31, 2025, of the Company’s directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.
|
ITEM 6. |
|
Exhibit No. |
Description |
| *†10.1a | Form of Notice of Grant of Strategic Phantom Performance Restricted Stock Units, including Terms and Conditions of Restricted Stock Units, granted under the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan |
| *†10.1b | Form of Notice of Grant of Market Phantom Performance Restricted Stock Units, including Terms and Conditions of Restricted Stock Units, granted under the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan |
|
(31) |
Rule 13a-14(a)/15d-14(a) Certifications |
|
(32) |
Section 1350 Certifications |
|
(101) |
XBRL |
|
*101 |
The following materials from Anika Therapeutics, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 as filed with the SEC on May 8, 2025, formatted in Inline XBRL (eXtensible Business Reporting Language), as follows: |
|
i. |
Condensed Consolidated Balance Sheets as of March 31, 2025 (unaudited) and December 31, 2024 (unaudited) |
|
ii. |
Condensed Consolidated Statements of Operations and Comprehensive Income for the Three Months Ended March 31, 2025 and March 31, 2024 (unaudited) |
|
iii. |
Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2025 and March 31, 2024 (unaudited) |
|
iv. |
Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2025 and March 31, 2024 (unaudited) |
|
v. |
Notes to Condensed Consolidated Financial Statements (unaudited) |
|
104 |
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
|
* |
Filed herewith. |
| † | Management contract or compensatory plan or agreement. |
|
** |
Furnished herewith. |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
ANIKA THERAPEUTICS, INC. |
|||
|
(Registrant) |
|||
|
Date: May 9, 2025 |
By: |
/s/ STEPHEN GRIFFIN |
|
|
Stephen Griffin |
|||
|
Executive Vice President, Chief Financial Officer and Chief Operating Officer |
|||
|
(Authorized Officer and Principal Financial Officer) |
|||